GLP-1 use has more than quadrupled since 2021 as obesity rates continue to show signs of decline • Epic Research (opens in new tab)

Epic Research: Semaglutide (Wegovy, Ozempic) received FDA approval for chronic weight management in 2021, followed by tirzepatide (Zepbound) in 2023, both demonstrating substantial weight loss in clinical trials.2,3 Demand has grown rapidly, raising questions about real-world uptake, prescribing patterns across clinical indications, and whether population-level BMI distributions are beginning to shift in response. The GLP-1 utilization tracker reports prescriptions per 100,000 patients for ea...